- Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent
-
Niscola P, Tendas A, Scaramucci L, Giovannini M, Fratoni S, de Fabritiis P
- KMID: 2172776
- Blood Res.
- 2015 Jun;50(2):113-114.
- doi: 10.5045/br.2015.50.2.113
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome
-
Kim HC, Kim SH, Ahn JH, Kwon HM, Choi JH, Kim TH, Lee JH
- KMID: 2269228
- Korean J Med.
- 2014 Oct;87(4):496-500.
- doi: 10.3904/kjm.2014.87.4.496
In randomized phase 3 clinical trials azacitidine has been shown to prolong survival in patients with higher-risk myelodysplastic syndrome (MDS). Therefore, azacitidine therapy should be considered for treating MDS patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia
-
Niscola P, Tendas A, Merola R, Orlandi G, Scaramucci L, de Fabritiis P
- KMID: 2172763
- Blood Res.
- 2015 Sep;50(3):181-182.
- doi: 10.5045/br.2015.50.3.181
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Azacitidine-induced Hepatotoxicity in a Patient with Myelodysplastic Syndrome
-
Kim JS, Lim JH, Yi HG, Park H, Lee MH, Kim CS
- KMID: 2083518
- Korean J Hematol.
- 2007 Jun;42(2):176-179.
- doi: 10.5045/kjh.2007.42.2.176
Hematopoietic stem cell transplantation remains the only curative option for myelodysplastic syndrome (MDS), but the prevalence of the disease in elderly people limits broad application of the procedure, particularly in... -
- CITED
-
- Close
- SHARE
-
- Close
- Dry Dressing for Epidermal Sloughing after Subcutaneous Azacitidine Injection in a Myelodysplastic Syndrome
-
Lee JY, Jung H, Kwon H, Jung SN
- KMID: 2267695
- Arch Plast Surg.
- 2014 Jul;41(4):425-426.
- doi: 10.5999/aps.2014.41.4.425
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
-
Niscola P, Grazia CD, Mazzone C, Tolu B, de Fabritiis P, Angelucci
- KMID: 2466597
- Blood Res.
- 2019 Dec;54(4):288-290.
- doi: 10.5045/br.2019.54.4.288
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations
-
Kim YJ, Jang JH, Kwak JY, Lee JH, Kim HJ
- KMID: 2172906
- Blood Res.
- 2013 Jun;48(2):87-98.
- doi: 10.5045/br.2013.48.2.87
Azacitidine is recommended for patients with higher-risk myelodysplastic syndromes (MDS) who are not eligible for intensive therapy or for patients with lower-risk MDS who have thrombocytopenia or neutropenia or have... -
- CITED
-
- Close
- SHARE
-
- Close
- New agents for the treatment of myelodysplastic syndromes
-
Jang JH
- KMID: 2257321
- Korean J Med.
- 2009 Feb;76(2):121-125.
Myelodysplastic syndromes (MDS) are a heterogenous group of clonal stem cell disorders commonly characterized by a hypercellular and dysplastic bone marrow, cytopenias resulting from impaired peripheral blood cell production, and... -
- CITED
-
- Close
- SHARE
-
- Close
- DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
-
Tran HT, Kim HN, Lee IK, Kim YK, Ahn JS, Yang DH, Lee JJ, Kim HJ
- KMID: 1782108
- J Korean Med Sci.
- 2011 Feb;26(2):207-213.
- doi: 10.3346/jkms.2011.26.2.207
DNA methyltransferase inhibitor, 5-azacitidine (AC) is effective in myelodysplastic syndromes (MDS) and can induce re-expression in cancer. We analyzed the methylation of 25 tumor suppressor genes in AC-treated MDS. Hypermethylation... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Effects of Hypomethylating Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome Who Received DNA-Damaging Chemotherapy for Metastatic Breast Cancer
-
Baek DW, Lee SJ, Sohn SK, Moon JH, Chae YS
- KMID: 2470901
- J Breast Cancer.
- 2019 Dec;22(4):647-652.
- doi: 10.4048/jbc.2019.22.e50
The cumulative risk of therapy-related myelodysplastic syndrome (t-MDS) in breast cancer patients exposed to chemotherapy and/or radiotherapy is significantly high compared to that in other cancer patients. This report reviews... -
- CITED
-
- Close
- SHARE
-
- Close
- Mixed-phenotype acute leukemia treated with decitabine
-
Lee JY, Lee SM, Lee JY, Kim KH, Choi MY, Lee WS
- KMID: 2373819
- Korean J Intern Med.
- 2016 Mar;31(2):406-408.
- doi: 10.3904/kjim.2014.353
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Enhanced differentiation of mesenchymal stromal cells by three-dimensional culture and azacitidine
-
Bae YJ, Kwon YR, Kim HJ, Lee S, Kim YJ
- KMID: 2375199
- Blood Res.
- 2017 Mar;52(1):18-24.
- doi: 10.5045/br.2017.52.1.18
BACKGROUND: Mesenchymal stromal cells (MSCs) are useful for cell therapy because of their potential for multilineage differentiation. However, MSCs that are expanded in traditional two-dimensional (2D) culture systems eventually lose... -
- CITED
-
- Close
- SHARE
-
- Close
- Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine
-
Hwang KL, Song MK, Shin HJ, Na HJ, Shin DH, Kim JK, Moon JH, Ahn JS, Song IC, Hong J, Lee GW, Chung JS
- KMID: 2270680
- Blood Res.
- 2014 Dec;49(4):234-240.
- doi: 10.5045/br.2014.49.4.234
BACKGROUND: Azacitidine (AZA) is standard care for patients with myelodysplastic syndrome (MDS) who have not had allogeneic stem cell transplantation. Chromosomal abnormalities (CA) including complex karyotype (CK) or monosomal karyotype... -
- CITED
-
- Close
- SHARE
-
- Close
- Reactivation of Silenced WT1 Transgene by Hypomethylating Agents: Implications for in vitro Modeling of Chemoimmunotherapy
-
Kwon YR, Son MJ, Kim HJ, Kim YJ
- KMID: 2150735
- Immune Netw.
- 2012 Apr;12(2):58-65.
- doi: 10.4110/in.2012.12.2.58
BACKGROUND: A cell line with transfected Wilms' tumor protein 1 (WT1) is has been used for the preclinical evaluation of novel treatment strategies of WT1 immunotherapy for leukemia due to... -
- CITED
-
- Close
- SHARE
-
- Close
- DNA Methylation of RUNX3 in Papillary Thyroid Cancer
-
Ko HJ, Kim BY, Jung CH, Chun SW, Mok JO, Kim YJ, Park HK, Kim CH, Kim SJ, Byun DW, Suh KI, Yoo MH, Kang SG
- KMID: 2432932
- Korean J Intern Med.
- 2012 Dec;27(4):407-410.
BACKGROUND/AIMS: The relationship between Runt-related transcription factor 3 (RUNX3) gene inactivation and various solid tumors has been reported; however, little information is available about RUNX3 in thyroid cancers. METHODS: We evaluated... -
- CITED
-
- Close
- SHARE
-
- Close
- Chromosomal Abnormalities in Myelodysplastic Syndrome with Near-tetraploidy: A Case Report
-
Kim HN, Lee HJ, Kim MH, Kim JS, Yang JH, Yoon SY, Lim CS, Lee KN
- KMID: 1435752
- Lab Med Online.
- 2012 Jan;2(1):47-50.
- doi: 10.3343/lmo.2012.2.1.8
Massive hyperdiploidy and tetraploidy are rare cytogenetic abnormalities in myelocytic malignancies, especially in myelodysplastic syndrome (MDS). These abnormalities are known to be associated with leukemogenesis, leukemic transformation and poor prognosis.... -
- CITED
-
- Close
- SHARE
-
- Close
- Enhancement of Osteogenic Differentiation by Combination Treatment with 5-azacytidine and Thyroid-Stimulating Hormone in Human Osteoblast Cells
-
Sun HJ, Song YS, Cho SW, Park YJ
- KMID: 2396809
- Int J Thyroidol.
- 2017 Nov;10(2):71-76.
- doi: 10.11106/ijt.2017.10.2.71
BACKGROUND AND OBJECTIVES: The role of thyroid-stimulating hormone (TSH) signaling on osteoblastic differentiation is still undetermined. The aim of this study was to investigate the effects of 5-aza-2′-deoxycytidine (5-azacytidine) on... -
- CITED
-
- Close
- SHARE
-
- Close
- Skeletal myogenic differentiation of human periodontal ligament stromal cells isolated from orthodontically extracted premolars
-
Song M, Kim H, Choi Y, Kim K, Chung C
- KMID: 1435400
- Korean J Orthod.
- 2012 Oct;42(5):249-254.
- doi: 10.4041/kjod.2012.42.5.249
OBJECTIVE: To investigate the stem cell-like characteristics of human periodontal ligament (PDL) stromal cells outgrown from orthodontically extracted premolars and to evaluate the potential for myogenic differentiation. METHODS: PDL stromal cells... -
- CITED
-
- Close
- SHARE
-
- Close
- Recovery of Genes Epigenetically Altered by the Histone Deacetylase Inhibitor Scriptaid and Demethylating Agent 5-Azacytidine in Human Leukemia Cells
-
Park E, Jeon E, Kim IH, Park S
- KMID: 1806201
- Genomics Inform.
- 2010 Dec;8(4):185-193.
Histone deacetylation and demethylation are epigenetic mechanisms implicated in cancer. Studies regarding the role of modulation of gene expression utilizing the histone deacetylase inhibitor scriptaid and the demethylating agent 5-azacytidine... -
- CITED
-
- Close
- SHARE
-
- Close
- The expression of survivin and its related genes in adipocyte-derived stem cell by demethylation
-
Yoon K, Lim YS, Yu SB, Kim DS, Ryu SJ, Kim KH, Jang TH, Kim SH
- KMID: 2299338
- Korean J Anesthesiol.
- 2010 Apr;58(4):383-390.
- doi: 10.4097/kjae.2010.58.4.383
BACKGROUND: Survivin is thought to contribute to stem cell maintenance partly by a hypomethylation mechanism. This study attempted to elucidate the signal transduction pathway of adipocyte-derived stem cells (ASCs) by... -
- CITED
-
- Close
- SHARE
-
- Close
